-
11:22:40 AM

OMER - Omeros Corporation

12/03/20 7:30 AM
Nasdaq : OMER
CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRIA(R) in Ambulatory Surgery Centers
Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros' cataract surgery drug OMIDRIA(R) (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment
RHEA-AI
neutral
11/18/20 9:00 AM
Nasdaq : OMER
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough ther
RHEA-AI
neutral
11/09/20 4:02 PM
Nasdaq : OMER
Omeros Corporation Reports Third Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended
RHEA-AI
neutral
10/16/20 8:30 AM
Nasdaq : OMER
Omeros' OMS906 Data Presented at Complement-based Drug Development Summit
Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system's alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made by Jason Cummings, Ph.D., Omeros' Associate Directo
RHEA-AI
neutral
10/15/20 8:00 AM
Nasdaq : OMER
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, and Alessandro Rambaldi, MD, Professor, Department of Oncology and
RHEA-AI
neutral